The BioHub - by Avetix

Thank you for tuning into another episode of Bio Hub! Today, we have the privilege of hosting Amit Kumar, a seasoned leader in the biotech industry and the current CEO & Chairman of Anixa Biosciences. Amit's experience is vast, spanning over two decades in leadership roles across the biotech landscape. He has previously served as CEO of CombiMatrix, a key player in molecular diagnostics, as well as GFF, and is also the Executive Chairman and co-founder of Actym Therapeutics, a company advancing immune oncology treatments. Now, at the helm of Anixa Biosciences, Amit is focused on addressing some of the most critical unmet needs in oncology. Under his leadership, the company is advancing cutting-edge therapies and vaccines aimed at tackling cancer, including innovative approaches in immunotherapy and vaccine development. Amit’s deep expertise, from startups to larger biotech companies, gives him a unique perspective on how to steer innovative science towards tangible clinical outcomes. We're excited to dive into his journey, the challenges and successes along the way, and what's next for Anixa and the broader biotech space.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. With nearly three decades of experience in biopharmaceutical development and manufacturing, Daniel's career spans both major pharmaceutical companies and innovative biotech firms. Prior to joining Vedanta, he held senior leadership roles at organizations like ContraFect Corporation, Merck Sharp Dohme Biologics, and Nuvelo Inc., where he contributed to advancing various drug candidates and therapeutic approaches. At Vedanta, Daniel is leading the charge in developing microbiome-based therapies to address immune-mediated and infectious diseases. His deep expertise in operations management and passion for team building have played a crucial role in shaping Vedanta's distinctive culture and advancing its mission. In this episode, we’ll explore Daniel’s professional journey, the ground-breaking work at Vedanta, the culture he has helped cultivate, and the opportunities and challenges facing the biotech industry.

Welcome back to another episode of The BioHub! Today, we’re thrilled to have Dr. Chris Haqq, Chief Medical Officer and Head of Research & Development at Elicio Therapeutics, join us. Chris is an expert in immuno-oncology with over 20 years of experience in the biotech industry. He has a remarkable track record in leading innovative therapies from concept to clinical stages, including his pivotal role in developing groundbreaking T cell therapies at Atara Biotherapeutics. In this episode, we’ll explore Elicio’s unique approach to cancer immunotherapy, Chris’s insights on the current biotech landscape, and what it takes to lead in such a challenging field.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We’re thrilled to have Martin Taylor, Senior Associate at F-Prime Capital. With a strong background in molecular biology and DNA research, Martin transitioned from the lab to venture capital, where he now helps identify and support innovative biotech companies. In this episode, we’ll explore Martin’s journey, his role at F-Prime, and his insights into the future of biotech. Enjoy and stay tuned.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We have an extraordinary guest, Angelo Stracquatanio, the Co-founder and CEO of Apprentice.io. Angelo is a visionary in the life sciences industry, leading the world's first cloud-based, manufacturing execution system for life sciences. With over $200M raised from leading VC funds and being ranked #60 fastest-growing software company on the Inc 5000, Apprentice.io is revolutionizing the industry with its innovative solutions. Enjoy and stay tuned.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We have the honor of hosting TJ Cradick, a pioneering leader in CRISPR technology. TJ is currently focused on CRISPR consulting and advising new gene-editing companies. He was previously the Chief Scientific Officer at Excision BioTherapeutics, where he led the development of CRISPR-based therapies for viral diseases. Before that, TJ was the 2nd US employee and Head of Genome editing at CRISPR Therapeutics and played a crucial role in the company's growth to a clinical-stage biotech. Having been in the space since 2000, we’ve got so much to cover. we'll be exploring TJ's journey, the challenges and triumphs of developing CRISPR technology, and the future of genome editing. Enjoy and stay tuned.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. we have an incredible episode lined up with a phenomenal guest, Raphael Ognar! Raphael is the President & CEO, and Co-Founder of NKILT Therapeutics, a biotech company developing innovative cell therapies to target leukemias and solid tumors. With over 25 years in the pharma and biotech industries, Raphael has a wealth of experience in oncology, hematology, and cell therapy. We'll explore the origin of NKILT, how Raphael found the right partners, and the challenges of securing funding for early-stage biotechs. He'll also share his journey at companies like Celgene and BMS, how he handles pressure, and his decision-making process as a CEO. Enjoy and stay tuned.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. we have the pleasure of hosting David Slack, CEO of Impilo Therapeutics. With over 30 years of experience in the biopharmaceutical industry, David has a proven track record in creating value for companies and investors through strategic partnerships and innovative financing transactions. David’s impressive career includes leadership roles at public and private biotech firms, as well as major pharmaceutical companies. He played a pivotal role in the merger of Cend Therapeutics with Caladrius Biosciences to form Lisata Therapeutics, and later co-founded Impilo Therapeutics to focus on nucleic acid-based medicine for treating solid tumor cancers. In this episode, we'll explore David's journey from R&D to business development, the challenges and opportunities in the biotech industry, and the exciting future of Impilo Therapeutics. Enjoy and stay tuned!

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Today, we have a special guest, Jerry McLaughlin, CEO of Life Biosciences. With over 30 years in the biopharmaceutical industry, Jerry has been instrumental in the development and commercialization of more than a dozen FDA-approved drugs. His impressive career started at Merck, and went on to leading roles at Endo, Neos Therapeutics, AgeneBio, and NuPathe. Life Biosciences is dedicated to extending healthy human lifespan by targeting the biological causes of aging. In this episode, we'll explore Jerry's journey from big pharma to biotech startups, his path to becoming a CEO, and the innovative work at Life Biosciences. Enjoy and stay Tuned!

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We're thrilled to have Dr. Arjun Goyal! Arjun is the Co-Founder and Managing Director of Vida Ventures, a leading life sciences venture capital firm with approximately $2 billion under management. He serves on the boards of companies like Scorpion Therapeutics and Quanta Therapeutics, and has played key roles in several high-profile investments and acquisitions. We'll dive into Arjun's journey from physician to investor, the story behind Vida Ventures, and what they look for in executives and new company investments. He'll also share insights into current market trends, his decision-making processes, and what sets his mindset apart. It's an absolute pleasure to welcome Dr. Arjun Goyal! Enjoy and stay tuned!